

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
05 June 2025 (05.06.2025)



(10) International Publication Number
WO 2025/117875 A1

(51) International Patent Classification:

A61K 31/506 (2006.01) A61P 35/04 (2006.01)
A61P 35/00 (2006.01)

(21) International Application Number:

PCT/US2024/057943

(22) International Filing Date:

29 November 2024 (29.11.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/604,042 29 November 2023 (29.11.2023) US
63/610,444 15 December 2023 (15.12.2023) US

(71) Applicant: **TYRA BIOSCIENCES, INC.** [US/US]; 2656
State Street, Carlsbad, California 92008 (US).

(72) Inventors: **TADA, Hiroomi**; c/o Tyra Biosciences, Inc.,
2656 State Street, Carlsbad, California 92008 (US). **BURN,
Timothy, Campbell**; c/o Tyra Biosciences, Inc., 2656 State
Street, Carlsbad, California 92008 (US).

(74) Agent: **LODISE, Stephanie** et al.; BAKER &
HOSTETLER LLP, 1735 Market Street, Suite 3300,
Philadelphia, Pennsylvania 19103-7501 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,

RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

(54) Title: COMPOUNDS FOR TREATING SOLID TUMORS HAVING ACTIVATING FGFR2 GENE ALTERATIONS



(57) Abstract: The disclosure provides methods of treating cancers that have activating FGFR2 gene alterations by administering a compound of Formula (I) as disclosed herein, or a pharmaceutically acceptable salt of a compound of Formula (I).

WO 2025/117875 A1